Image: HyperView Imaging System. Photo: courtesy of Business Wire.

US-based HyperMed Imaging has launched a new non-invasive and portable diagnostic imaging device, HyperView Imaging System, in the country.

The US Food and Drug Administration (FDA) approved, fast, handheld and battery-operated system is designed to assess tissue oxygenation and perfusion during the potential circulatory compromise.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Eliminating the need for patient contact and injectable contrast, the new device captures colour-coded images that comprise data on clinician critical information, including oxyhaemoglobin levels (Oxy), deoxyhaemoglobin levels (Deoxy) and oxygen saturation (O2Sat) in superficial tissue.

The information is intended to aid in determining the presence or absence of adequate blood perfusion required by a patient to heal a wound or maintain healthy tissue.

The imaging system is expected to allow more informed decisions on the necessary course of action by providing insights on arterial as well as venous sufficiency in the surface tissue.

“The imaging system is expected to allow more informed decisions on the necessary course of action.”

Using the HyperView system, clinicians could also obtain perfusion levels before and after vascular interventional procedures such as peripheral bypass, stent placement or balloon angioplasty.

HyperMed Imaging president and CEO Mark Darty said: “The low-cost, speed, portability, ease of use and high-quality data and imagery provide clinicians with a new class of tool to rapidly assess perfusion and locate ischemic tissue.

“This information helps caregivers better understand potential circulatory compromise and allow more informed treatment of complications of vascular disease and diabetes.”

The imaging device has applications in wound care, vascular intervention and reconstructive surgery, according to the firm’s sales vice-president Annette Plishka.